INTRODUCTION
Biliary atresia (BA) is the major cause of neonatal cholestatic jaundice, and untreated BA can cause chronic liver disease, hepatic failure, and death in children (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . BA is well established as the leading indication for liver transplantation (LT) in children in Korea. Furthermore, BA is the most common cause of LT in infants under 12 months (12) .
The incidence of BA is slightly higher in Eastern countries (1.04 to 1.79/10,000 live births) than in Western countries (0.42 to 0.71/10,000) (1-3,5-9,13-21). This difference in incidence rates may be due to a combination of factors, including genetics, environmental factors, and infectious pathogens (5, 7, 20) . The incidence of BA in Korea has not been reported. The aim of this study was to investigate the incidence and clinical outcomes of BA in Korea.
MATERIALS AND METHODS

Data source
We used the Health Insurance Review and Assessment Service (HIRA) database based on the Korean universal health insurance system. We retrieved information about patient's age, sex, diagnosis and treatments, and diagnosis, which was presented by the Korean Classification of Disease, 7th Revision (KCD-7) code.
Patient selection and definition of cases
We extracted the following information from the database: KCD-7, Q442, or Q443 BA status in patients under 18 years of age from January 2011 to December 2015. We defined 2 BA groups: the "newly diagnosed BA group, " which included patients with BA who received the Kasai operation (Q735-Q737) or LT (Q814) before their first birthday, and the "total BA group, " which included all BA patients between 0 and 18 years of age during the 5-year study period.
The newly diagnosed BA group was used to calculate the incidence of BA and the percentage of congenital anomalies because definite and suspected BA cases could not be discriminated using the KCD-7. The total BA group was used to calculate the percentages of complications and LT.
The incidence of BA was calculated by dividing newly diagnosed BA patients by the population of live births. We defined the date of diagnosis as the first day that a patient visited a medical facility for BA. Month of diagnosis was grouped into 4 seasons: winter (December-February), spring (March-May), summer (June-August), and autumn (September-November). Incidence is presented as the number of BA patients per 10,000 live births with a 95% confidence interval (CI).
https://doi.org/10.3346/jkms.2017.32. 4.656 We investigated the percentage of congenital anomalies such as spleen anomalies, situs inversus, and heart disease in the newly diagnosed BA group. If different congenital anomalies were present in a single patient, each anomaly was counted separately. Percentages of complications and LT were calculated by dividing the number of applicable cases by the size of the total BA group. We also evaluated patients subjected to endoscopic variceal bleeding control. For the total BA group, we determined the number of patients who underwent LT during the 5-year study period and the number of patients who had already undergone LT prior to 2011.
Statistical analysis
We analyzed the data using SAS Enterprise version 6.1 (SAS Institute, Cary, NC, USA). The 95% CI of BA incidence was calculated using the Poisson distribution. The seasonal, annual, and gender variation in the occurrence of BA was measured using the Poisson regression test. We used linear regression to evaluate the linear trend in LT over time. The incidence of BA was 1.06/10,000 (95% CI, 0.93-1.19), (females 1.28, males 0.92). The incidence of BA was 1.4 times higher for female than male patients, and this difference was statistically significant (P = 0.200) ( Table 1) . When the months were grouped into 1 of 4 seasons, the rate from June through August (summer) was 2 times higher than that from December through February (winter) (P < 0.010) (Fig. 1 ). There was no statistically significant difference in annual incidence.
Ethics statement
Congenital anomalies
Congenital anomalies were found in 38/240 of patients in the newly diagnosed BA group (15.8%); specifically, this group included 2 patients with spleen anomalies (0.8%) and 1 patient with situs inversus (0.4%). Congenital heart diseases comprised major associated congenital anomalies (15 patients, 6.3%), which ranged from relatively minor disease (atrial septal defect, patent ductus arteriosus) to life threatening severe disease (hypoplastic left heart syndrome, pulmonary atresia). Two patients had more than 2 congenital heart diseases. Ten patients (4.2%) had biliary anomalies (choledochal cyst or duplication of the biliary duct), and 8 patients (3.3%) were diagnosed with intestinal anomalies such as small bowel atresia, malrotation, tracheoesophageal fistula, and Meckel's diverticulum. One patient with congenital cystic lung and another with congenital vesicoureteral reflux were reported (Table 2) .
Complications
The total BA group included 963 BA patients. Two hundred thirty-one patients (24%) experienced at least 1 episode of cholan- gitis, and their median age was 1 year (Table 2 ). There were 60 patients (6.2%) who had esophageal and gastric varices, with a median age of 7 years. Gastrointestinal bleeding was reported in 42 patients (4.4%), and there were 44 patients (4.6%) who received endoscopic bleeding control (EBC). Three patients received repetitive EBC, with 1 patient who received EBC 6 times during a 5-year period. Two patients developed hepatocellular carcinoma (HCC) before they turned 18 years (at age 3 and 7 years) and 2 other patients showed secondary pulmonary hypertension (at age 4 and 13 years).
LT
One hundred twenty-four patients with BA underwent LT (including re-transplantation) during the 5-year study period, and the median age at LT was 1 year. Sixty-five of these 124 patients (52.4%) received deceased donor LT (DDLT); split LT was the preferred approach (34.0%), and 7 of these 65 patients received re-DDLT (split DDLT in 4 cases and total DDLT in 3 cases). The remaining 59 of the aforementioned 124 patients (47.6%) received living donor LT (LDLT); typically, the left lateral segment was used (37.3%), and 2 of these 59 patients received re-LDLT using the left lateral segment ( Table 3 ). The cases of deceased DDLT (split DDLT) increased (P = 0.100), while LDLT decreased over time (P = 0.720), but there was no statistically significant difference. Fifty-three of 115 patients (46.0%) receiv ed LT prior to 1 year of age. Eleven patients (8.7%) received re-LT, and 3 of these 11 patients were less than 1 year of age.
Three hundred one of the 963 patients in the total BA group (31.3%) received LT, including 124 patients who first received LT during the 5-year study period and 177 patients who underwent LT prior to 2011.
DISCUSSION
This is the first report of BA incidence in Korea using the national health system database and the entire population of children born in the country. We identified the differences in BA incidence by gender and season, and we also reported the associated congenital anomalies and clinical outcomes of BA.
The incidence of BA in Korea (1.06/10,000) is similar to that in other East Asian countries, including Japan (1.0-1.1) (15, 17) and Taiwan (1.5-1.8) (7, 9) , but higher than that in European countries such as France (0.5) (2), the UK (0.6) (3, 19) , Scotland (0.7) (16), and Switzerland (0.6) (18) as well as the USA cities of Atlanta (0.7) (1) and New York (0.9) (5). Because our incidence calculations only included patients who underwent the Kasai operation or LT before their first birthday, we may not have accounted for certain patients who died before receiving either of these operations or ceased receiving treatment.
The etiology of BA is unknown. However, environmental factors, including infections, toxins, and ischemia, are purported to cause this disease. Several studies describe seasonal and geographic variation in the incidence of BA (1,2,5,7,9,16-19,21,22) . In Atlanta, significant seasonal clustering of BA was reported, with rates 3 times higher from December through March than rates from April through July (1, 7, 19) . We also reported the seasonal variation of BA, and these results are consistent with environmental factors such as viral infection. This epidemiologic observation suggests that further investigation into the timing of possible viral infection around the perinatal period and subsequent identification of BA is necessary.
However, other studies insist that genetic factors are important to the pathogenesis of BA, showing the ethnic and gender variations in the incidence of BA (1, 6, 7, 13, 17, 19, 23) . In our study, the incidence of BA was 1.4 times higher in females than in males; this finding is consistent with the results of many previous studies (1, 6, 7, 13, 17, 19, 23) .
In this study, 15.8% of 240 BA patients had associated congenital anomalies; similar findings have been obtained in other studies (with corresponding percentages of 21.5%, 20.8%, 19.6%, 14.0%, and 12.6% for the UK, Switzerland, Japan, USA, and Canada, respectively) (1, 3, 6, 15, 18, 20, 24) . Congenital heart disease (6.3%) was the major associated anomaly in our study, much like in other countries such as Canada (7.5%) and the USA (8.7%), followed by biliary anomalies (4.2%) and gastrointestinal anomalies (3.3%) (20, 24) .
In our total BA group, 2 HCC patients (0.2%, 3 and 7 years of age) were identified. At King's College Hospital, 3 of 387 BA patients (0.8%) developed histologically proven HCC, which was detected at a median age of 2.1 years (range 1.8-4.9 years); in Belgium, an infant who was affected by BA complicated by HCC when he was 6 months old was treated via LT, suggesting that HCC can develop at an early age in children with BA (25) (26) (27) . Pulmonary hypertension was reported in 5 of the 617 BA patients who underwent LDLT (0.5%); this condition is more common among patients who undergo LDLT than among BA patients with naïve livers because the former patients are LT candidates with end-stage liver disease (28, 29) . We also found 2 secondary pulmonary hypertension patients (of 4 and 13 years of age) in the total BA group. LT, including re-LT, was performed in 124 BA patients during the 5-year study period, and the median age at LT was 1 year. Other studies have found median ages for LT for BA of 1.1 years in Taiwan, 11-14 months in Canada, and 12 months in the UK and Switzerland, which are similar to the age calculated in our study (3, 7, 18, 20) .
In a study of patients from Seoul National University Hospital in Korea, a total of 152 children received LT from 1992 to 2010; 92 of these patients (60.5%) had BA, and 33 (35.9%) patients received LT for BA before 1 year of age (12) . Our study produced similar results: 53 of 115 patients (46%) received LT before 1 year of age. In Asian countries, LDLT has been the main form of LT because of a shortage of deceased donors attributable to cultural and ethical concerns (12) . However, the number of pediatric DDLT increased from 2006 to 2010 due to increased total deceased donation rates and the pediatric split graft policy (30) . In our report, the number of cases involving DDLT (split DDLT) increased over the study period, whereas the number of cases involving LDLT decreased during this time. Three hundred one of the 963 patients (31.3%) received LT; this rate is slightly lower than that observed in the USA (40.3%) but higher than the corresponding rates in Taiwan (26%) and Croatia (20.7%) (7, 8, 24) .
Our study has some limitations. The HIRA database only contains 5 years (2011-2015) of data; thus, this investigation utilized relatively short-term data. The database did not provide information regarding mortality; therefore, we could not examine survival rates.
In conclusion, this is the first report describing the incidence and clinical outcomes of BA in Korea using the national health insurance system database. In Korea, BA incidence is relatively higher than those in other Western countries but is similar to that in other East Asian countries and shows statistically significant female dominancy and seasonal clustering.
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